Summary This study examined the efficacy and safety of zonisamide as monotherapy in pediatric patients with epilepsy. Seventy-seven children with epilepsy (ages 8 months-15 years) were treated with zonisamide. Nine patients were withdrawn early because of side effects; these patients were included in side effect but not efficacy analyses. Zonisamide dosages were initiated at approximately 2 mg/kg per day and adjusted for each patient individually to a maximum of 12 mg/kg per day. Among 44 patients with cryptogenic/symptomatic partial epilepsy, 36 (82%) became seizure free; 4 (9%) had a ≥50% reduction in seizure frequency; and 4 (9%) had no change in seizures with zonisamide treatment. Of 11 patients with cryptogenic/symptomatic generalized epilepsy, 10 (91%) became seizure free, and 1 experienced no change with zonisamide treatment. Similarly, 4 patients (100%) with idiopathic partial epilepsy, and 8 of 9 patients (89%) with idiopathic generalized epilepsy became seizure free with zonisamide treatment; in the last group, 1 experienced no change. Thirty patients (39%) reported side effects, including somnolence (11.7%), decreased spontaneity (7.8%), anorexia (6.5%), and rash (6.5%). Thus, zonisamide is effective for partial seizures with or without secondarily generalized seizures in children and should be considered a broad-spectrum antiepilepsy agent.
Introduction
Whenever possible, monotherapy should be a goal for patients with epilepsy. This study examines the safety and efficacy of zonisamide as monotherapy in pediatric patients with epilepsy. *Corresponding author. Tel.: +81 3 3833 8381; fax: +81 2 3831 9488.
Methods

Patients
The study group consisted of 77 children with epilepsy (ages 8 months-15 years) who were patients from the Department of Pediatrics, Keio University Hospital, and the pediatric departments of Keio University-affiliated hospitals. These patients were observed for sufficient periods to determine their baseline values of frequency and severity of seizures before zonisamide treatment. Nine patients dropped out at an early stage of zonisamide administration because of somnolence and anorexia. These 9 patients were excluded from the efficacy analysis, but were included in the study of adverse effects. Excluding these 9 patients, the study group comprised 68 patients. Fifty had never taken antiepilepsy drugs (AEDs); the remaining 18 were nonresponders to AEDs. In these 18 patients, the previous AEDs were gradually decreased and discontinued during zonisamide administration. The method for gradual decrease and discontinuation was not fixed, but was left up to individual physicians. As this study was conducted before the market introduction of zonisamide, patients' parents provided verbal informed consent before zonisamide treatment began.
Study design
Zonisamide administration was initiated using a standard procedure for pediatric zonisamide administration in Japan. That is, approximately 2 mg/kg per day of zonisamide was administered in 2 equally-divided doses in the morning and evening. When no change, or only a partial decrease in seizures was noted following an initial dose, the dosage was then increased by 1-2 mg/kg per day every 1-2 weeks. Provided no unacceptable adverse effects occurred, zonisamide could be increased to up to a dose of 12 mg/kg per day as necessary to decrease seizures.
Efficacy against seizures, adverse effects, and serum concentration was evaluated. Zonisamide concentrations were determined using blood samples taken 2-4 h after morning administration, at 2 weeks or more following a change in dosage.
Evaluation of efficacy
In general, reductions in both seizure frequency and seizure severity are important criteria for efficacy, but because evaluation of seizure severity would have depended on a physician's subjective judgment, we evaluated only seizure frequency as follows:
• ''Excellent response''-Patients with ≥1 seizure/ month before study entry who became seizure free for ≥3 months after zonisamide administration. Also included were patients with <1 seizure/month before zonisamide who became seizure free for a period of at least 3 times longer than the maximal seizure-free period before zonisamide treatment.
• ''Good response''-Patients who experienced a ≥50% reduction in seizures.
• ''Poor response'' or ''no response''-Patients who experienced a <50% reduction in seizures, or no effect, respectively.
Evaluation of safety
Adverse effects were investigated by means of interviews, clinical assessments, and blood tests (complete blood count, glutamic oxaloacetic transaminase, glutamic pyruvate transaminase, gamma glutamyl traspeptidase, blood urea nitrogen, creatinine, calcium, potassium, alkaline phosphatase, protein analysis, immunoglobulin, antinuclear antibody, and urinalysis), using samples collected monthly throughout the study. Table 1 shows the 68 patients in the study group classified according to the 1989 International League Against Epilepsy classification. Forty-eight patients had localization-related epilepsies; 44 had symptomatic/cryptogenic epilepsy; and 4 had idiopathic epilepsy. These 4 patients had benign childhood epilepsy with centrotemporal spikes (Rolandic epilepsy). Twenty patients had generalized epilepsies; of these, 11 had symptomatic/cryptogenic epilepsy, and 9 had idiopathic epilepsy. Patients with West syndrome, Lennox-Gastaut syndrome, childhood absence epilepsy, and severe myoclonic epilepsy in infancy were excluded because of ethical problems probably due to poor efficacy of zonisamide in Japan trials. 1, 2 Patients' ages at the time of zonisamide administration ranged from 8 months to 15 years, 8 months (mean = 8 years, 3 months). Zonisamide administration periods ranged from 6 months to 5 years, 8 months (mean = 1 year, 9 months) among responders (patients with ''excellent'' and ''good'' responses) and from 3 to 5 months (mean = 4 months) among nonresponders (patients with ''poor'' or ''no responses'').
Patient clinical profiles
Results
Efficacy
The efficacy of zonisamide treatment by epileptic syndrome is shown in Table 2 . In localization-related epilepsy, efficacy was ''excellent'' in 36 of 44 symptomatic/cryptogenic patients (82%); ''good'' in 4 patients (9%); and ''poor'' or ''ineffective'' in 4 patients (9%). Efficacy was ''excellent'' in 
all 4 idiopathic epilepsy patients. In generalized epilepsy, efficacy was ''excellent'' in 10 of 11 symptomatic/cryptogenic epilepsy patients (91%) and ''excellent'' in 8 of 9 idiopathic epilepsy patients (89%). Table 3 shows efficacy against seizure by epileptic syndrome and seizure type. Seizure type was diagnosed by seizure history and interictal EEG primarily, with ictal EEG used in only a few cases; video EEG was not used. In localization-related epilepsy patients, efficacy was ''excellent'' in symptomatic/cryptogenic epilepsy patients with simple partial seizures (89%), complex partial seizures (79%), and secondarily generalized tonic- clonic seizures (82%). Combining these patients and ''good'' response patients, responders accounted for approximately 90%.
In patients with symptomatic/cryptogenic generalized epilepsy, groups for each seizure type included only a small number of patients, but efficacy was seen against tonic-clonic, clonic, and atonic seizures (Table 3) . Because atonic seizures were not evaluated by video-EEG, inclusion of tonic or myoclonic elements is unknown. Of the 9 patients with idiopathic epilepsy, all patients had tonic-clonic seizures, and among these, 8 (89%) were ''excellent'' responders. Fig. 1 shows an ictal EEG recording of a patient with symptomatic localization-related epilepsy as- sociated with tuberous sclerosis. The patient was 25 years old and an EEG had been recorded 11 years earlier. The EEG showed the immediate appearance of rhythmic slow wave at 3-3.5 Hz after the onset of a seizure, mainly in frontocentral cortex of the right hemisphere. There was no epileptic discharge during interictal period. Despite receiving nitrazepam and phenobarbital, the patient had experienced about 10 seizures a day at age 14. Zonisamide had initially been used as adjunctive therapy. Seizures had disappeared 11 days after starting zonisamide treatment. The doses of nitrazepam and phenobarbital were gradually reduced, and finally the patient had been treated with zonisamide as monotherapy (300 and 400 mg/day; dose was in-creased because of body weight gain; plasma zonisamide concentration was 20 and 20.3 g/mL, respectively.) As of his last visit, he had been free from seizures for 11 years. Fig. 2 shows the relationship between efficacy and serum concentration of zonisamide. There was no apparent relationship between efficacy and serum zonisamide concentration in any seizure types. As shown in Fig. 2 , only 2 patients (closed triangle) discontinued zonisamide treatment. They were rapidly titrated with zonisamide (2 mg/kg per day a week or more) because of frequent seizures, and zonisamide concentrations in their serum exceeded 40 g/mL. They were discontinued from zonisamide treatment because of adverse events, and unsatisfactory reduction of seizures.
Safety
Side effects were reported for 30 patients (39%). Table 4 presents data on adverse effects of zonisamide, with data from the present study contrasted with data from combined multicenter clinical studies of 1008 adult and pediatric patients in Japan (which includes adverse effects both in zonisamide add-on and zonisamide monotherapy). 2 Adverse events were observed in 30 out of 77 patients (39%) in our study. By comparison, in combined multicenter studies in Japan 2 , adverse events were observed in 517 out of 1008 patients (51.3%), but in only 16 out of the 55 patients receiving zonisamide monotherapy (29%). As shown in Table 4 , adverse effects characteristic of zonisamide include impairment of higher mental function and gastrointestinal disorders. However, evaluation of the former is subjective and qualitative, and there is a need for additional objective, quantitative evaluation. The incidence of subjective hypohidrosis was low in the multicenter trials at 1 in 1008 (0.1%) 2 ; in our study 2 of 77 (2.6%, subjective evaluation) experienced hypohidrosis that disappeared at the end of summer. Fig. 3 shows serum zonisamide concentrations obtained immediately after manifestation of adverse effects following zonisamide administration. Patients whose adverse events were transient and disappeared included 2 patients in whom zonisamide dosage was decreased temporarily, and patients in whom dosage was continued without change. There was no clear relationship between occurrence of adverse events and serum zonisamide concentrations as shown in Fig. 3. A decreased serum IgA level (14 mg/dL) without a propensity to infection was found in a 5-year-old girl with zonisamide monotherapy about 4 months after the initiation of treatment. Her serum IgA concentration was 132 mg/dL before zonisamide treatment. Although zonisamide treatment was continued thereafter, the serum IgA level in the patient remained unchanged. Table 5 shows the efficacy of zonisamide in pediatric patients: in the left column, results of a multicenter study of children by Oguni et al. 1 ; in the center column, our study results; and, in the right column, results from the multicenter trials. 2 In the 3 data sets, the efficacy of zonisamide was evaluated by seizure types, not by epileptic syndromes. For partial seizures, zonisamide appears to show high efficacy, especially in the pediatric studies, but this efficacy is also attributable to the large number of patients who had received no previous treatment (i.e., newly-diagnosed patients). One other important point is the inclusion of cases in which zonisamide as add-on therapy suppressed seizures and transition to zonisamide monotherapy was successful. Zonisamide also appears to be effective as monotherapy of generalized seizures; the small number of cases indicates a need for further study. Data for the incidence of hypohidrosis from this study was compared with that of previous reports in Table 6 Hypohidrosis associated with zonisamide in Japan.
Discussion and conclusions
Reference
Number of patients with hypohidrosis/total number of patients Open-label multicenter trials Japan (Table 6 ). In the premarketing stage, the incidence was 1 in 1008 patients (0.1%) and barely received attention. After market introduction, cases reported among children subsequently increased. Many of the cases were observed in the hot period of summer. Okumura et al. 3 have hypothesized that zonisamide may suppress the perspiration function of sweat glands, but further study is needed. In many cases, hyperthermia provided an opportunity to reveal hypohidrosis. Because the condition is often transient, there is no need to discontinue zonisamide for this reason alone except in special circumstances, and symptomatic treatment is acceptable. However, if zonisamide is used in tropical or subtropical regions, the potential for greater problems exists.
In interpreting these data, it is important to note characteristics of patient samples differ in quality and quantity in the pre-and postmarketing studies of new AEDs, including zonisamide. Premarketing studies proceed with a patient group presumed to be somewhat homogeneous. In postmarketing phases, patient groups tend to be more heterogeneous. There are also fewer patients in premarketing phases than in postmarketing phases. In addition, the physicians managing AEDs during premarketing studies are virtually all specialists; this is not true in postmarketing studies.
In the postmarketing reappraisal of the efficacy and safety of zonisamide determined during premarketing phases, certain phenomena should be considered. Frequent clinical experience with postmarketing use of new AEDs includes; (1) a pattern of use for many epileptic syndromes, (2) an unanticipated expansion of the efficacy spectrum; (3) a corresponding appearance of unanticipated adverse effects; and (4) some change in the status of adverse effects deemed extremely rare during premarketing trials.
Finally, there are 2 important points to be made about the advantageous use of zonisamide regarding patient selection and administration protocol. First, although subsequent experience may change the current thinking, use of zonisamide should be precluded in West syndrome, Lennox-Gastaut syndrome, and SME in infancy because there are other effective treatments or because of doubts about zonisamide efficacy. Secondly, to minimize adverse effects and heighten efficacy, the following protocol is recommended: (1) initiate zonisamide with 1-2 mg/kg per day; (2) for patients with moderately frequent seizures, increase zonisamide gradually on the order of 1 mg/kg per day every 1-2 weeks; and (3) for patients in whom seizure control is inadequate, increase zonisamide gradually to a serum concentration of 40-50 g/mL, depending on the patients, with due attention to mental activity and gastrointestinal symptoms.
In conclusion, although our current experience of monotherapy is limited to a small number of patients, zonisamide may become a first-line AED for both adults and children. However, further evaluation is needed with respect to efficacy, safety, and applications in generalized epilepsy.
